Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 alone or with tremelimumab in metastatic pancreatic ductal adenocarcinoma
NL-OMON42744Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in pancreatic adenocarcinoma (PDAC), sponsored by AstraZeneca. Started Jan 2016; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON42744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42744.